This from Egoli-SHAW Analyst Comments: Resmed's Q4 and FY result August 14, 2002 Q4 and FY result Resmed (RMD) released their Q4 and FY result to the market this morning local time. Full year revenue increased 32% to US$204.1M (SHAW expectations were for revenue of $204.8M). Net Income increased 222% to US$37.5M (SHAW expectations of $36.0M). US sales increased 27% which appears to be ahead of the market growth rate, while international sales increased 13%. German sales increased 10% on the March quarter, with prescription volumes growing. There is a longer than usual delay in German between prescriptions and recognition of revenue - thus a lagging effect on evidence of recovery in that country. No dividend was declared. Regarding the share buy-back: only 290,047 shares of a total 4M shares have been repurchased to date, leaving room for further share price support. regardsBarcoo
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnin